- Home
- DCOM vs MLYS Comparison
DCOM vs MLYS Comparison
Compare DCOM & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DCOM
- MLYS
- Stock Information
- Founded
- DCOM 1864
- MLYS 2019
- Country
- DCOM United States
- MLYS United States
- Employees
- DCOM N/A
- MLYS N/A
- Industry
- DCOM Major Banks
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- DCOM Finance
- MLYS Health Care
- Exchange
- DCOM Nasdaq
- MLYS Nasdaq
- Market Cap
- DCOM 1.2B
- MLYS 1.0B
- IPO Year
- DCOM 1996
- MLYS 2023
- Fundamental
- Price
- DCOM $28.69
- MLYS $14.80
- Analyst Decision
- DCOM Buy
- MLYS Strong Buy
- Analyst Count
- DCOM 4
- MLYS 4
- Target Price
- DCOM $33.88
- MLYS $27.00
- AVG Volume (30 Days)
- DCOM 284.9K
- MLYS 903.4K
- Earning Date
- DCOM 07-22-2025
- MLYS 08-12-2025
- Dividend Yield
- DCOM 3.47%
- MLYS N/A
- EPS Growth
- DCOM N/A
- MLYS N/A
- EPS
- DCOM 0.62
- MLYS N/A
- Revenue
- DCOM $295,419,000.00
- MLYS N/A
- Revenue This Year
- DCOM $46.03
- MLYS N/A
- Revenue Next Year
- DCOM $16.60
- MLYS N/A
- P/E Ratio
- DCOM $46.08
- MLYS N/A
- Revenue Growth
- DCOM N/A
- MLYS N/A
- 52 Week Low
- DCOM $20.78
- MLYS $8.24
- 52 Week High
- DCOM $37.60
- MLYS $18.38
- Technical
- Relative Strength Index (RSI)
- DCOM 61.16
- MLYS 53.41
- Support Level
- DCOM $27.93
- MLYS $13.44
- Resistance Level
- DCOM $29.26
- MLYS $14.70
- Average True Range (ATR)
- DCOM 0.78
- MLYS 0.67
- MACD
- DCOM 0.18
- MLYS 0.12
- Stochastic Oscillator
- DCOM 83.53
- MLYS 99.44
About DCOM Dime Community Bancshares Inc.
Dime Community Bancshares Inc operates as a holding company. It gathers deposits from customers within its market area and via the internet and invests them in multifamily residential, commercial real estate, commercial and industrial (C&I) loans, and one-to-four family residential real estate loans, as well as mortgage-backed securities, obligations of the U.S. government and government- sponsored enterprises (GSEs), and corporate debt and equity securities. The company has one reportable segment which is Community Banking.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.